Share on StockTwits

Cerulean Pharma (NASDAQ:CERU) issued its quarterly earnings data on Thursday. The company reported ($3.70) earnings per share for the quarter, missing the analysts’ consensus estimate of ($3.52) by $0.18, AmericanBankingNews.com reports.

Shares of Cerulean Pharma (NASDAQ:CERU) opened at 5.73 on Thursday. Cerulean Pharma has a 52 week low of $5.05 and a 52 week high of $8.06. The stock’s 50-day moving average is $6.60 and its 200-day moving average is $6.60. The company’s market cap is $109.0 million.

Several analysts have recently commented on the stock. Analysts at Leerink Swann initiated coverage on shares of Cerulean Pharma in a research note on Tuesday, May 6th. They set an “outperform” rating and a $13.00 price target on the stock. On a related note, analysts at Wedbush initiated coverage on shares of Cerulean Pharma in a research note on Tuesday, May 6th. They set an “outperform” rating and a $12.00 price target on the stock. Finally, analysts at JMP Securities initiated coverage on shares of Cerulean Pharma in a research note on Tuesday, May 6th. They set an “outperform” rating and a $14.00 price target on the stock.

Cerulean Pharma Inc is a clinical-stage oncology-focused company applying its tumor targeting platform.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.